Intrexon Corp’s Stock Is Sell After Today’s Bearish Options Activity

 Intrexon Corp's Stock Is Sell After Today's Bearish Options Activity

In today’s session Intrexon Corp (XON) recorded an unusually high (500) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious XON decrease. With 500 contracts traded and 4594 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: XON161118P00024000 closed last at: $0.9 or 30.8% down. About 355,327 shares traded hands. Intrexon Corp (NYSE:XON) has declined 24.10% since April 5, 2016 and is downtrending. It has underperformed by 26.05% the S&P500.

Analysts await Intrexon Corp (NYSE:XON) to report earnings on November, 14. They expect $-0.23 EPS, up 32.35% or $0.11 from last year’s $-0.34 per share. After $-0.29 actual EPS reported by Intrexon Corp for the previous quarter, Wall Street now forecasts -20.69% EPS growth.

Intrexon Corp (NYSE:XON) Ratings Coverage

Out of 6 analysts covering Intrexon (NYSE:XON), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. Intrexon has been the topic of 10 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Wunderlich maintained the shares of XON in a report on Tuesday, August 11 with “Buy” rating. The rating was initiated by Bank of America on Wednesday, October 14 with “Neutral”. The stock of Intrexon Corp (NYSE:XON) earned “Buy” rating by Wunderlich on Monday, October 19. JMP Securities initiated the stock with “Market Outperform” rating in Tuesday, May 3 report. The company was upgraded on Wednesday, November 11 by Mizuho. Wunderlich maintained it with “Buy” rating and $70 target price in Monday, July 27 report. The rating was downgraded by JP Morgan to “Overweight” on Tuesday, August 11. Stifel Nicolaus initiated it with “Buy” rating and $69 target price in Monday, September 21 report. The firm earned “Neutral” rating on Monday, January 25 by Mizuho. On Tuesday, August 11 the stock rating was downgraded by Mizuho to “Underperform”.

According to Zacks Investment Research, “Intrexon Corporation is a biotechnology company. It provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. Intrexon Corporation is based in Germantown, Maryland.”

Insitutional Activity: The institutional sentiment decreased to 1.12 in 2016 Q2. Its down 0.22, from 1.34 in 2016Q1. The ratio dropped, as 37 funds sold all Intrexon Corp shares owned while 40 reduced positions. 18 funds bought stakes while 68 increased positions. They now own 98.85 million shares or 1.45% less from 100.31 million shares in 2016Q1.
Utah Retirement System accumulated 0.01% or 10,000 shares. Natl Bank Of Montreal Can accumulated 400 shares or 0% of the stock. New York State Common Retirement Fund accumulated 0.01% or 258,615 shares. Jefferies Group Incorporated Ltd Liability holds 95 shares or 0% of its portfolio. Dimensional Fund Advsr Limited Partnership holds 13,897 shares or 0% of its portfolio. Frontier Capital Mngmt Com Lc has 90,800 shares for 0.02% of their US portfolio. Legal And General Gp Public Limited Com accumulated 5,819 shares or 0% of the stock. Moreover, Blackrock Fund Advsr has 0% invested in Intrexon Corp (NYSE:XON) for 541,260 shares. Sabby Management Limited Liability Company holds 0.15% or 120,359 shares in its portfolio. Columbus Circle Investors holds 54,209 shares or 0.01% of its portfolio. Bluemountain Cap Limited Liability Com, a New York-based fund reported 30,862 shares. Pnc Services Group accumulated 23,550 shares or 0% of the stock. Moreover, Third Security Limited Company has 79.4% invested in Intrexon Corp (NYSE:XON) for 61.90 million shares. Moreover, Hightower Advisors Limited Company has 0.01% invested in Intrexon Corp (NYSE:XON) for 19,091 shares. Moreover, Claar Advsrs Limited Liability Com has 0.61% invested in Intrexon Corp (NYSE:XON) for 50,000 shares.

Insider Transactions: Since May 13, 2016, the stock had 2 insider purchases, and 0 selling transactions for $1.11 million net activity. $104,484 worth of Intrexon Corp (NYSE:XON) was bought by Nimrodi Nir. 41,830 shares with value of $1.00M were bought by KIRK RANDAL J on Friday, May 13.

Intrexon Corporation forms collaborations to create biologically based products and processes using synthetic biology. The company has a market cap of $3.09 billion. The Firm designs, manufactures and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. It currently has negative earnings. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

XON Company Profile

Intrexon Corporation (Intrexon), incorporated on June 1, 2010, forms collaborations to create biologically based products and processes using synthetic biology. The Company’s domestic activities are in California, Florida, Maryland, and Virginia, and its primary international activities are in Belgium and Hungary. The Firm designs, manufactures and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.

More recent Intrexon Corp (NYSE:XON) news were published by: Prnewswire.com which released: “AquaBounty Technologies Inc. (“AquaBounty” or the “Company”) Filing of Form 10 …” on November 07, 2016. Also Fool.com published the news titled: “Better Buy: Ziopharm Oncology, Inc. vs. Intrexon Corporation” on October 14, 2016. Nasdaq.com‘s news article titled: “Commit To Purchase Intrexon Corp At $17.50, Earn 16.6% Using Options” with publication date: October 25, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment